Teva Pharmaceuticals Secures FDA Labeling Approval for Discontinued Oxaliplatin Injectable (NDA022160)
Teva Pharmaceuticals has received FDA approval for a supplemental labeling application (submission 16) for its Oxaliplatin injectable (NDA022160) on October 31, 2024. Despite this regulatory update, both 50MG/10ML and 100MG/20ML strengths of Teva's Oxaliplatin are officially listed as "Discontinued" by the FDA, indicating no active market presence for this specific product.
Regulatory Update for Teva's Discontinued Oxaliplatin Injectable (NDA022160)
On October 31, 2024, the U.S. Food and Drug Administration (FDA) granted approval for a supplemental New Drug Application (sNDA) submission number 16, pertaining to labeling changes for Teva Pharmaceuticals' Oxaliplatin injectable (NDA022160). This standard review priority approval, documented in a letter dated November 4, 2024, and an updated label dated November 1, 2024, updates the official prescribing information for the drug. Teva Pharmaceuticals originally secured FDA approval for its Oxaliplatin injectable on August 7, 2009, under NDA022160. This initial approval covered two strengths: 50MG/10ML (5MG/ML) and 100MG/20ML (5MG/ML), both administered intravenously. However, a critical detail for all stakeholders is that both product presentations of Teva's Oxaliplatin (product numbers 001 and 002) are currently listed with a "Discontinued" marketing status by the FDA. This means that while regulatory updates continue to be processed, Teva Pharmaceuticals is not actively marketing or distributing this specific Oxaliplatin formulation in the United States. For regulatory affairs heads, this highlights the ongoing compliance obligations even for products no longer actively sold. It underscores the need to maintain accurate labeling and documentation, irrespective of commercial status. Procurement directors and supply chain VPs must recognize that this specific Teva product is not available for sourcing, necessitating alternative strategies for securing Oxaliplatin.
Commercial Landscape and Sourcing Implications Post-Discontinuation
The "Discontinued" marketing status of Teva Pharmaceuticals' Oxaliplatin injectable (NDA022160) significantly shapes the commercial landscape for this specific product. Despite the recent FDA approval of a labeling supplement on October 31, 2024, this action does not signal a re-entry or renewed commercial push by Teva for this particular formulation. Instead, it reflects a commitment to regulatory compliance even for withdrawn products. For business development executives, this means that the market share previously held by Teva's Oxaliplatin is now open to other manufacturers of generic oxaliplatin. While the source text and knowledge graph do not identify alternative suppliers, the absence of Teva's product creates a clear void that other pharmaceutical companies with approved oxaliplatin formulations would naturally fill. Procurement directors must therefore focus their sourcing efforts on other FDA-approved generic versions of oxaliplatin. The discontinuation of Teva's product necessitates a robust supplier diversification strategy to ensure continuity of supply for this critical antineoplastic agent. Relying on a single source or failing to identify active market participants could lead to supply disruptions. Supply chain VPs should review their current supplier matrices to confirm adequate coverage and mitigate risks associated with product discontinuations.
Operational and Regulatory Compliance for Discontinued Products
The FDA's approval of a labeling supplement for a discontinued product, such as Teva's Oxaliplatin (NDA022160), underscores a nuanced aspect of pharmaceutical regulation. It demonstrates that regulatory obligations, including maintaining up-to-date labeling, can persist long after a product has ceased active commercial distribution. This is crucial for regulatory affairs heads, who must ensure that even legacy or withdrawn products remain compliant with current FDA standards to avoid potential liabilities or future regulatory scrutiny. For operations and finance leaders, this implies that resources must still be allocated for regulatory maintenance, even for non-revenue-generating products. This includes staff time for preparing and submitting sNDAs, as well as managing associated documentation and communications with the FDA. Understanding these long-tail regulatory requirements is essential for accurate budgeting and strategic planning within the global chemical and life sciences industry. Business development executives should consider how such regulatory continuity for discontinued products might influence decisions regarding product lifecycle management and market withdrawal strategies. The cost and effort associated with maintaining compliance for a "Discontinued" product can be substantial, influencing the overall profitability and strategic value assessment of a drug throughout its entire lifecycle, not just its active marketing phase. This event serves as a reminder that regulatory affairs is a continuous function.